EP2603505A1 - Procédé pour fabriquer du linézolid - Google Patents

Procédé pour fabriquer du linézolid

Info

Publication number
EP2603505A1
EP2603505A1 EP10747831.5A EP10747831A EP2603505A1 EP 2603505 A1 EP2603505 A1 EP 2603505A1 EP 10747831 A EP10747831 A EP 10747831A EP 2603505 A1 EP2603505 A1 EP 2603505A1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
group
acid
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10747831.5A
Other languages
German (de)
English (en)
Inventor
Petr Bartos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon BV filed Critical Synthon BV
Publication of EP2603505A1 publication Critical patent/EP2603505A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

  • the present invention relates to an improved process for making the compound linezolid.
  • Linezolid is a pharmaceutically active compound useful as an antibacterial agent, e.g. for the treatment of diabetic food infections caused by Gram-positive bacteria. It is represented by the formula (I).
  • compositions are a sterile isotonic solution for an i.v. infusion, a tablet for oral administration and an aqueous suspension for oral administration. They are marketed, i.e., under brand name ZYVOX by Pfizer.
  • linezolid has one asymmetric carbon in the molecule allowing for 2 enantiomers; the marketed compound is the (S)-enantiomer.
  • linezolid is present as a free base.
  • This amine precursor (II) may be made from various starting materials, e.g.:
  • the starting compound (III) may be made from the corresponding tosylate or of general formula (VII) below (WO 2005/099353).
  • the starting compound (IV) may be made from the same tosylate or chloride as sub a) (WO2005/099353) or by a cyclization of the oxazolidine ring (WO 99/24393,
  • R2 is a chlorophenyl, bromophenyl or 2,4,-dichlorophenyl moiety (WO 2007/1 16284).
  • L is a suitable leaving group, for instance a halogen or an alkyl-or aryl sulfonyloxy group,
  • the present invention relates to a discovery of an improved process of making linezolid, which is simple in respect to process conditions and provides low amounts of reaction side products.
  • the invention provides a process for making the compound 3-(3- fluoro-4-(morpholin-4-yl)phenyl)-2-oxooxazolidin-5(S)-ylmethyl)amine of formula (II) and/or an acid addition salt thereof
  • the leaving group is preferably a halo group or an alkyl- or aryl-sulfonyloxy group.
  • the compound (II) is converted to linezolid by acetylation, preferably as an acid addition salt and more preferably in water.
  • the compound (IXb) is a novel compound and thus represents a specific aspect of the invention.
  • the compound (IXa) and/or the compound (IXb) may be used in the making of linezolid.
  • the starting material in the process of making linezolid according to the present invention is a compound of general formula (VII)
  • L is a leaving group, typically a halo group or an alkyl- or aryl-sulfonyloxy group.
  • the "halo” group comprises chloro- or bromo-group, preferably chloro- group.
  • the "alkyl” comprises C1-C4 alkyl group and preferably a methyl group.
  • the "aryl” comprises phenyl group, which may be optionally substituted by at least one C1-C4 alkyl group, a nitro- group, a hydroxyl group, an C1-C4 alkoxy group, and is preferably p-tolyl or p-nitrophenyl group.
  • the compounds are known in the art or may be prepared according to processes known in the art, e.g. from corresponding hydroxyl-methyl compounds of the formula (X).
  • the second reaction partner is a metal salt of diformylamide of the formula (VIII).
  • the "Me + " is typically sodium or potassium, preferably sodium.
  • the compound (VIII) is known in the art and is commonly obtainable by a reaction of the corresponding metal methoxide with formamide, see US5488188 and US5599986. It may be isolated as a solid and stored at ambient conditions.
  • the reaction between the compounds (VII) and (VIII) may typically proceed in an inert solvent, which preferably is a polar aprotic solvent, for instance ⁇ , ⁇ -dimethyl formamide, dimethyl sulfoxide , acetonitrile, N-methylpyrrolidone, ⁇ , ⁇ -dimethylacetamide or acetone and mixtures thereof.
  • an inert solvent which preferably is a polar aprotic solvent, for instance ⁇ , ⁇ -dimethyl formamide, dimethyl sulfoxide , acetonitrile, N-methylpyrrolidone, ⁇ , ⁇ -dimethylacetamide or acetone and mixtures thereof.
  • molar ratio between compound (VII) and compound (VIII) is from 1 :1 to 1 :3, preferably of from about 1:1.1 to about 1 : 1.7.
  • the reaction temperature is typically from 50 to 100°C, preferably from 60 to 90°C. At these conditions, the reaction time is about 0.5
  • the volatile residues are advantageously removed, e.g. by evaporation, and the residual metal salts are also removed, e.g. by an extraction with water.
  • the reaction product comprises a mixture of compounds of formula (IXa) and (IXb).
  • both compounds depends on the relative amount of the compound (VIII) in respect to the compound (VII).
  • the reaction mixture comprises only the compound (IXa) and/or only the compound (IXb).
  • both compounds (IXa) and (IXb) are equally convertible into the amine of the formula (II) in the next step, there is no objective need to separate them or enhance their mutual ratio in the mixture.
  • both compounds of the reaction mixture are separated by a suitable separation technique, for instance for analytical purposes.
  • the compounds (IXa) and (IXb) may also be obtained in the form of an acid addition salt, e.g. as a hydrochloride, hydrobromide, sulphate, nitrate , phosphate, formate, acetate, propionate, oxalate, malonate, maleate, fumarate, citrate, malate etc.
  • any of the compounds (IXa) and (IXb) and/or a mixture thereof is converted, in a next step, into the compound of formula (II) by a mild acid hydrolysis.
  • the acid useful for this purpose is a strong mineral or organic acid, for instance hydrochloric acid, sulphuric acid, phosphoric acid,or hydrobromic acid. In general, a molar extent of the acid is used.
  • the hydrolysis may proceed in a solvent, which may be water, a lower alcohol (C1-C4 aliphatic alcohol) or a mixture of both.
  • Typical reaction temperature is between 0 and 80 °C.
  • the course of reaction may be monitored by a suitable analytical technique, e.g. HPLC or TLC.
  • the hydrolysis step may be advantageously combined with the preceded step in a one- pot arrangement.
  • the product of the reaction comprises the raw amine compound of formula (II). It is formed after the hydrolysis as the corresponding acid addition salt (e.g. hydrochloride or dihydrochloride), which may be optionally neutralized into free amine, if necessary, by a treatment with an equivalent of a base, optionally followed by an extraction.
  • the raw compound (II) and/or its acid addition salt, e.g. a hydrochloride or acetate may be, if necessary, purified by known processes and/or isolated in any solid state form , e.g. that as disclosed in US 2006/0258655. Hydrochloride or acetate salt of the compound (II) are the preferred salts.
  • Crude or purified amine (II) may be converted to linezolid by a reaction with an acetyl halide or acetic acid anhydride, under conditions known well in the art.
  • the acetylation may be performed under conditions of Schotten-Baumann reaction or a modification thereof .
  • the name "Schotten-Baumann reaction conditions" indicates the use of an acetylation agent in a presence of a base.
  • the acetylation runs in a two-phase solvent system, consisting of water and a water immiscible organic solvent. A base is present within the water phase, which neutralizes the acid generated in the reaction, while the starting materials and product remain in the organic phase.
  • a water immiscible organic solvent are toluene, dichloromethane and/or diethyl ether.
  • (II) is converted, with or without isolation, into a water soluble acid addition salt of an inorganic acid or acetic acid, e.g. into a hydrochloride, hydrobromide, sulphate, nitrate, phosphate, and/or acetate.
  • the salt is dissolved in water, the solution is cooled as close to 0°C as possible, the acetylation agent, preferably acetic anhydride, is added, and the acetylation process is started by continuous addition of a base (preferably an inorganic base, such as sodium carbonate or sodium acetate).
  • a base preferably an inorganic base, such as sodium carbonate or sodium acetate.
  • the desired linezolid precipitates from the reaction mixture as it is not soluble therein. In this modification, organic solvents are completely avoided.
  • the produced linezolid may be isolated in any solid state form known in the art [ Form I (J.Med.Chem. 39(3), 673 (1996)), Form II (WO 01/057035, US 6,559,305), Form III (WO 2005/035530) and many others (WO 2006/004922 , US 2006/0142283), amorphous form (WO 2007/026369) and hydrated forms (US 2006/1 1 1350, EP 20033960 )] and/or may be converted in a suitable acid addition salt.
  • the linezolid prepared by the process of the present invention can be formulated and used in pharmaceutical compositions.
  • a suitable pharmaceutical composition may comprise linezolid and at least one pharmaceutically acceptable excipient.
  • the compositions are useful as antibacterial agents, in treating various diseases caused by some types of bacteria, by administering an effective amount thereof to a patient in need of such treatment. In particular, they are useful in treatment of diabetic food infections caused by Gram-positive bacteria.
  • the effective amounts range from 1 mg to 500 mg, expressed as the amount of linezolid base, per day.
  • the solid was mixed with 10 ml of methanol an 0.438ml of concentrated hydrochloric acid ( 5.00 mmol) was added.
  • the reaction mixture was warmed up in an oil bath to 65°C and stirred at this temperature for 2 hours.
  • the mixture was evaporated at diminished pressure and then co-evaporated with toluene ( 60°C, 25 mbar) to yield 220 mg of white glassy solid.
  • the reaction mixture was transferred to a 500 ml round bottom flask and cooled down in an ice- water bath.
  • Dichoromethane 150 ml was charged to the flask.
  • the mixture was vigorously stirred and a solution of NaOH (54.0 g) in water (100 ml) was added, such that the internal temperature did not exceed 20°C.
  • the mixture was filtered.
  • the filtrate was transfered to a 500 ml separatory funnel and the organic layer was separated. The filter cake was discarded.
  • the water layer was extracted with dichloromethane (2 x 50 ml).
  • the combined organic layer was dried over Na2S04 (25 g), filtered, and concentrated (60°C, 50 mbar) to provide the product as a tan crystalline solid (18.87 g).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un procédé pour fabriquer le composé 3-(3-fluoro-4-(morpholin-4-yl)phényl)-2-oxo-oxazolidin-5(S)-ylméthyl)amine de formule (II) et/ou un sel d'addition d'acide de celui-ci comprenant b) la réaction du composé de formule (VII) dans lequel L est a groupe partant, avec un sel de métal de diformylamide de formule (VIII) dans lequel Me+ est un cation de sodium ou de potassium, b) la soumission du produit de réaction de l'étape (a) comprenant, seul ou en mélange, des composés de formule (IXa) et/ou (IXb), à une réaction avec un acide, et la fabrication de linézolid par acétylation du composé de formule (II), et les composés (IXa) et (IXb) dans la fabrication de linézolid.
EP10747831.5A 2010-08-11 2010-08-11 Procédé pour fabriquer du linézolid Withdrawn EP2603505A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2010/005209 WO2012019632A1 (fr) 2010-08-11 2010-08-11 Procédé pour fabriquer du linézolid

Publications (1)

Publication Number Publication Date
EP2603505A1 true EP2603505A1 (fr) 2013-06-19

Family

ID=42829562

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10747831.5A Withdrawn EP2603505A1 (fr) 2010-08-11 2010-08-11 Procédé pour fabriquer du linézolid

Country Status (3)

Country Link
EP (1) EP2603505A1 (fr)
CN (2) CN103140487A (fr)
WO (2) WO2012019632A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2603252T3 (es) 2012-11-09 2017-02-24 Synthon Bv Proceso para preparar linezolid
WO2015068121A1 (fr) 2013-11-06 2015-05-14 Unimark Remedies Ltd. Procédé pour la préparation de la forme cristalline i de linézolide et ses compositions
CN104262280B (zh) * 2014-09-22 2016-07-20 山东华生化学股份有限公司 一种利奈唑酮的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035530A1 (fr) 2003-10-16 2005-04-21 Symed Labs Limited Nouvelle forme cristalline du linezolid
WO2006008754A1 (fr) 2004-07-20 2006-01-26 Symed Labs Limited Nouveaux intermediaires pour linezolide et composes correspondants

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US5599986A (en) 1994-09-29 1997-02-04 Hoechst Marion Roussel Inc. Process for the preparation of alkali metal salts of diformylamide
US5488188A (en) 1994-09-29 1996-01-30 Merrell Dow Pharmaceuticals Inc. Process for the preparation of (E)-1-amino-2-(fluoromethylene)-4-(p-fluorophenyl)butane, novel processes for preparing an intermediate thereof, and novel intermediates thereof
CZ298060B6 (cs) 1996-04-11 2007-06-06 Pharmacia & Upjohn Company Zpusob prípravy oxazolidinonu
KR100619639B1 (ko) 1997-11-07 2006-09-06 파마시아 앤드 업존 캄파니 엘엘씨 옥사졸리디논의 제조 방법
US6444813B2 (en) 2000-02-02 2002-09-03 Pharmacia & Upjohn Company Linezolid-crystal form II
AR027261A1 (es) 2000-02-02 2003-03-19 Upjohn Co Linezolid forma cristalina ii
DE602004009344T2 (de) 2004-04-19 2008-07-10 Symed Labs Ltd., Hyderabad Neues verfahren zur herstellung von linezolid und verwandten verbindungen
EP1745028A2 (fr) 2004-06-29 2007-01-24 Teva Pharmaceutical Industries Ltd Formes solides du linezolide et leurs procedes de preparation
CA2572054A1 (fr) 2004-06-29 2006-01-12 Teva Pharmaceutical Industries Ltd. Forme cristalline iv de linezolide
CN101128442A (zh) * 2005-02-24 2008-02-20 特瓦制药工业有限公司 制备利奈唑胺中间体的方法
EP1866295A2 (fr) 2005-02-24 2007-12-19 Teva Pharmaceutical Industries Ltd Procedes de preparation d'intermediaire linezolid
WO2007026369A1 (fr) 2005-08-29 2007-03-08 Symed Labs Limited Nouvelle forme amorphe du linezolid
DE502006002556D1 (de) 2005-09-06 2009-02-26 Ernst Schenkel Wassergekühltes Rostelement
MX2008012941A (es) * 2006-04-07 2008-10-15 Pfizer Prod Inc Un procedimiento novedoso para preparar agentes antibacterianos de oxazolidinona.
EP2033960A3 (fr) 2007-09-04 2009-04-29 Dipharma Francis S.r.l. Formule d'hydrate cristalline de linézolide et sels de linézolide
WO2009063505A2 (fr) 2007-10-08 2009-05-22 Usv Limited Processus de préparation de (s) (n-[[3-[3-fluoro-4-(4-morpholinyle) hen l -2-oxo-5-oxazolidine l méthyl]acétamide
EP2163547A1 (fr) * 2008-09-16 2010-03-17 Unión Químico Farmacéutica, S.A. (UQUIFA) Procédé de préparation d'un agent antibactérien de type oxazolidinone et ses intermédiaires

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035530A1 (fr) 2003-10-16 2005-04-21 Symed Labs Limited Nouvelle forme cristalline du linezolid
WO2006008754A1 (fr) 2004-07-20 2006-01-26 Symed Labs Limited Nouveaux intermediaires pour linezolide et composes correspondants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012019632A1

Also Published As

Publication number Publication date
WO2012019862A1 (fr) 2012-02-16
CN103119040A (zh) 2013-05-22
WO2012019632A1 (fr) 2012-02-16
CN103140487A (zh) 2013-06-05

Similar Documents

Publication Publication Date Title
WO2006010831A1 (fr) Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
US20040242556A1 (en) Novel crystalline form of cefdinir
KR20150041650A (ko) (ｓ)-3-(4-((4-(모르폴리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온 및 이의 약학적으로 허용가능한 형태의 제조를 위한 공정
WO2008149228A1 (fr) Procédé perfectionné pour la préparation de (2s,3s,5s)-5-amino-2-n,n-dibenzylamino-3-hydroxy-1,6-diphénylhexane sensiblement pur
WO2022214645A1 (fr) Procédés et intermédiaires pour la préparation de rélugolix
KR101653570B1 (ko) 신규한 옥사졸리디논 유도체 및 이를 함유하는 의약 조성물
US10934289B2 (en) Solid state forms of venetoclax and its process for the preparation there of
EP2603505A1 (fr) Procédé pour fabriquer du linézolid
US20220306650A1 (en) Process and polymorphic forms of bictegravir and its pharmaceutically acceptable salts or co-crystals thereof
US11236050B2 (en) Polymorphs of 4-[3-chloro-4-(n′-cyclopropyl ureido)phenoxy] -7-methoxyquinoline-6-carboxamide, its salts and process for the preparation thereof
EP2603506A1 (fr) Procédé pour fabriquer du linézolid
EP2573084A1 (fr) Nouvelles formes cristallines de rivaroxaban et leurs procédés de préparation
WO2007040326A1 (fr) Nouveau dérivé de formamide oxazolidinone et son procédé de préparation
JP2000229978A (ja) オキサゾリジノン及び抗菌剤としてのそれらの使用
KR19980084677A (ko) 옥사졸리디논 유도체, 이의 제조방법 및 그를 함유한 항균제 조성물
KR101128029B1 (ko) (ｒ)-3-(3-플루오로-4-(1-메틸-5,6-다이하이드로-1,2,4-트리아진-4(1ｈ)-일)페닐)-5-(치환된 메틸)옥사졸리딘-2-온 유도체의 제조방법
EP2917189B1 (fr) Procédé de production de linézolide
KR100467309B1 (ko) 옥사졸리디논유도체및그의제조방법및항균제조성물
AU2018374838A1 (en) Process for preparing acylated amphetamine derivatives
US20110071302A1 (en) Process for preparing intermediate compound for synthesizing an antiulcerant
HUT65885A (en) Process for preparing heterocyclyl-phenoxyalkyl-piperidinylpyridazines and pharmaceutical compositions containing them
RU2190597C2 (ru) Способ получения антагонистов nmda (n-метил-d-аспартата)
AU2016399299B2 (en) Crystalline form
JPH04270272A (ja) アミノアルキルモルホリン誘導体の製造法
KR100463111B1 (ko) 신규한옥사졸리디논유도체및제조방법및그를함유하는항균제조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130311

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

TPAC Observations by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20131030